EVLO Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 12:09):

Stats
Today's Volume	1 279.00
Average Volume	37 990.00
Market Cap	839 040
EPS	$0 ( 2024-03-21 )
Next earnings date	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2023-11-07	Bodmer Mark	Buy	6 625	Common Stock
2023-11-08	Bodmer Mark	Sell	3 163	Common Stock
2023-11-07	Bodmer Mark	Sell	6 625	Restricted Stock Units
2023-11-07	Mchale Duncan	Buy	6 500	Common Stock
2023-11-08	Mchale Duncan	Sell	3 103	Common Stock

INSIDER POWER
86.67
Last 96 transactions
Buy: 11 679 076 \| Sell: 749 652

Evelo Biosciences Inc Correlation

10 Most Positive Correlations
YJ	0.981
RPTX	0.978
CLFD	0.977
LGMK	0.977
CREG	0.972
JAGX	0.971
CFRX	0.965
HOL	0.963
MMAT	0.963
SLNG	0.963

10 Most Negative Correlations
BRIV	-0.986
ENTF	-0.986
ORIA	-0.984
PRLH	-0.984
PPYA	-0.984
IVCP	-0.983
HCNE	-0.983
PWUP	-0.983
BIOS	-0.983
CBRG	-0.983

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Evelo Biosciences Inc Financials

Annual	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-26.28

Q3	2023
Revenue:	$0
Gross Profit:	$-793 000 (0.00 %)
EPS:	$-0.710

Q2	2023
Revenue:	$0
Gross Profit:	$-1.62M (0.00 %)
EPS:	$-3.78

Q1	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-4.57

Financial Reports:

No articles found.

Evelo Biosciences Inc

Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in Phase 2 clinical trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19. The company also develops EDP1867, an inactivated investigational oral biologic, which is in Phase 1b for the treatment of inflammatory diseases; EDP2939, an extracellular vesicle investigational oral biologic for the treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.